Identification of GPX4 as a therapeutic target for lung adenocarcinoma after EGFR-TKI resistance.

ABSTRACT:

Background

Tyrosine kinase inhibitor (TKI) treatment has significantly improved the prognosis of oncogenic-driven lung adenocarcinoma (LUAD). However, drug resistance limits the long-term benefits of patients. Therefore, there is a pressing need to explore the mechanism of TKI resistance and identify new therapeutic targets. It is possible to overcome TKI resistance by inducing tumor cell death through a new process called ferroptosis. Aberrations in ferroptosis, which is a kind of regulated cell death (RCD), has been confirmed to be involved in the development and progression of multiple tumors, and is closely related to patient survival. At present, the role of ferroptosis in TKI resistance remains unclear.

Methods

Ferroptosis-related factors were isolated by expression ch

SUBMITTER: Zhang C 

PROVIDER: S-EPMC9186177 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature